Dabur Pharma receives final approval from USFDA for its Epirubicin Injection

Dabur Pharma Ltd has announced that the Company has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Epirubicin Injection 50mg and 200mg.

The Stock closed the day at Rs.75.55, up by Rs.1.85 or 2.51%. The stock hit an intraday high of Rs.76.40 and low of Rs.73. The total traded quantity was 20419 compared to 2 week average of 16391.

Source : Equity Bulls

Keywords